A Case of Drug Eruption with Localized ExfoliativeDermatitis Induced by Imatinib Mesylate.
- Author:
Kwang Ho YOO
1
;
Yong Kwan Rho RHO
;
Ji Young KIM
;
Kapsok LI
;
Seong Jun SEO
;
Chang Kwun HONG
Author Information
1. Department of Dermatology, College of Medicine, Chung-Ang University, Seoul, Korea. drseo@hanafos.com
- Publication Type:Case Report
- Keywords:
Imatinib mesylate;
Localized exfoliative dermatitis
- MeSH:
Benzamides;
Dermatitis, Exfoliative;
Drug Eruptions;
Female;
Fusion Proteins, bcr-abl;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Mesylates;
Philadelphia Chromosome;
Piperazines;
Protein-Tyrosine Kinases;
Pyrimidines;
Imatinib Mesylate
- From:Korean Journal of Dermatology
2008;46(10):1435-1438
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Imatinib mesylate (Gleevec(R), formerly known as STI571) is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase created by the Philadelphia chromosome abnormality in patients with chronic myeloid leukemia (CML). Between 7 to 21% of the patients treated with imatinib mesylate have been reported to develop adverse cutaneous reactions. However, exfoliative dermatitis related to imatinib mesylate is rare and there is only one previously reported case of this in the Korean literature. We report here on a woman with localized exfoliative dermatitis that developed after administering imatinib mesylate for treating her CML.
